OraSure Technologies, Inc. (NASDAQ:OSUR) Shares Acquired by Northern Trust Corp

Northern Trust Corp lifted its holdings in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 6.7% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 693,887 shares of the medical instruments supplier’s stock after purchasing an additional 43,628 shares during the quarter. Northern Trust Corp owned about 0.93% of OraSure Technologies worth $2,505,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in OSUR. Renaissance Technologies LLC grew its holdings in shares of OraSure Technologies by 23.1% in the fourth quarter. Renaissance Technologies LLC now owns 2,774,443 shares of the medical instruments supplier’s stock valued at $10,016,000 after purchasing an additional 521,400 shares in the last quarter. Archon Capital Management LLC grew its holdings in shares of OraSure Technologies by 145.1% in the fourth quarter. Archon Capital Management LLC now owns 827,777 shares of the medical instruments supplier’s stock valued at $2,988,000 after purchasing an additional 490,034 shares in the last quarter. Peapod Lane Capital LLC acquired a new position in shares of OraSure Technologies in the fourth quarter valued at approximately $1,730,000. American Century Companies Inc. grew its holdings in shares of OraSure Technologies by 11.4% in the fourth quarter. American Century Companies Inc. now owns 2,345,837 shares of the medical instruments supplier’s stock valued at $8,468,000 after purchasing an additional 240,224 shares in the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new position in shares of OraSure Technologies in the fourth quarter valued at approximately $664,000. Institutional investors and hedge funds own 93.50% of the company’s stock.

Insider Buying and Selling at OraSure Technologies

In other news, CFO Kenneth J. Mcgrath acquired 64,000 shares of the company’s stock in a transaction on Thursday, February 27th. The shares were bought at an average cost of $3.15 per share, with a total value of $201,600.00. Following the transaction, the chief financial officer now owns 371,013 shares in the company, valued at approximately $1,168,690.95. This trade represents a 20.85% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director John P. Kenny acquired 47,659 shares of the company’s stock in a transaction on Thursday, February 27th. The stock was purchased at an average cost of $3.17 per share, for a total transaction of $151,079.03. Following the completion of the transaction, the director now owns 70,915 shares in the company, valued at approximately $224,800.55. The trade was a 204.93% increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have bought 190,284 shares of company stock valued at $600,348. Insiders own 3.90% of the company’s stock.

OraSure Technologies Stock Down 1.9%

NASDAQ OSUR opened at $2.52 on Friday. OraSure Technologies, Inc. has a 52 week low of $2.36 and a 52 week high of $4.98. The firm has a 50 day moving average of $2.99 and a two-hundred day moving average of $3.51. The stock has a market capitalization of $188.50 million, a PE ratio of 16.80 and a beta of 0.42.

OraSure Technologies announced that its Board of Directors has approved a share buyback plan on Monday, March 24th that permits the company to repurchase $40.00 million in outstanding shares. This repurchase authorization permits the medical instruments supplier to repurchase up to 15.6% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s management believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Evercore ISI restated an “in-line” rating and issued a $3.00 price objective on shares of OraSure Technologies in a report on Monday, May 19th. Wall Street Zen upgraded shares of OraSure Technologies from a “sell” rating to a “hold” rating in a report on Saturday, May 17th.

OraSure Technologies Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.